Clinical Trial

Testing Experimental Medication in Healthy Subjects

Study Description

CD71 in Dried Blood Spots in Healthy Males

Understand the effect of recombinant EPO (rEPO) boosting and microdosing on the hematological module of the Athlete Biological Passport (ABP) - Measure the change in CD71 longitudinally in subjects from both cohorts - Assess whether rEPO administration can be detected in a dried blood spot (DBS) using recent advances in analytical methodologies - Compare windows of rEPO detection using both Athlete Biological Passport models and direct detection using analytical methods in urine, blood, and DBS

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - EPOGEN® (epoetin alfa)

Active drug

Normal Saline

Placebo

Additional Information

Official Study Title

Evaluation of CD71 Expression in a Dried Blood Spot Following rEPO Administration

Clinical Trial ID

NCT04073849

ParticipAid ID

e0RzKb